S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
Moscow says 50 Ukrainian drones shot down as attacks spark fires at Russian power stations
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
NYSE:NKGN

NKGen Biotech (NKGN) Stock Price, News & Analysis

$1.11
+0.25 (+29.21%)
(As of 04/19/2024 ET)
Today's Range
$0.83
$1.62
50-Day Range
$0.80
$2.56
52-Week Range
$0.78
$12.88
Volume
4.92 million shs
Average Volume
380,471 shs
Market Capitalization
$25.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NKGN stock logo

About NKGen Biotech Stock (NYSE:NKGN)

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

NKGN Stock Price History

NKGN Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Why Is NKGen Biotech (NKGN) Stock Up 62% Today?
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
NKGen Biotech Inc (NKGN)
NKGN NKGen Biotech, Inc.
NKGen Biotech GAAP EPS of -$2.48
NKGen Biotech Inc NKGN
See More Headlines
Receive NKGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/21/2024
Next Earnings (Estimated)
7/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$4.55 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.19) per share

Miscellaneous

Free Float
18,245,000
Market Cap
$25.22 million
Optionable
Not Optionable
Beta
0.54
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Paul Y. Song M.D. (Age 58)
    CEO & Chairman
    Comp: $36.58M
  • Mr. Sangwoo Park (Age 54)
    Executive Director
    Comp: $576k
  • Mr. James A. Graf (Age 59)
    Interim CFO
  • Mr. Pierre Gagnon (Age 52)
    Chief Operating Officer
  • Ms. Yoonmi Kang
    Vice President of Technical Operations
  • Dr. Yong Man Kim Ph.D. (Age 59)
    Chief Scientific Officer
  • Ms. Denise A. Chua CLS
    MBA, MT (ASCP), Vice President of Investor Relations & Corporate Communications
  • Ms. Irene Chang
    Vice President of Human Resources
  • Mr. Ryan Park C.F.A.
    SVP of Financial Planning & Analysis and Corporate Strategy

NKGN Stock Analysis - Frequently Asked Questions

How have NKGN shares performed in 2024?

NKGen Biotech's stock was trading at $2.75 on January 1st, 2024. Since then, NKGN shares have decreased by 59.8% and is now trading at $1.1060.
View the best growth stocks for 2024 here
.

When is NKGen Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 16th 2024.
View our NKGN earnings forecast
.

How do I buy shares of NKGen Biotech?

Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:NKGN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners